Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : to Present at Jefferies Gene Therapy Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/01/2018 | 10:19am EDT

NOVATO - Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Jefferies Gene Therapy Summit on Thursday, September 27, 2018 at 8:00am ET in New York.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Contact:

Danielle Keatley

Tel: 415-475-6876

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
05/10ULTRAGENYX PHARMACEUTICAL : to Present at Bank of America Merrill Lynch Healthca..
AQ
05/07ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
05/06ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
05/06ULTRAGENYX : 1Q Earnings Snapshot
AQ
05/06Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
GL
05/03ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement (for..
AQ
04/30Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results a..
GL
04/17ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure (form 8-K)
AQ
04/16ULTRAGENYX PHARMACEUTICAL : Announces UX007 Granted Fast Track Designation and R..
AQ
04/11Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 1..
GL
More news
Financials ($)
Sales 2019 97,3 M
EBIT 2019 -387 M
Net income 2019 -377 M
Finance 2019 355 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 29,8x
EV / Sales 2020 13,7x
Capitalization 3 255 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 75,5 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC31.51%3 255
GILEAD SCIENCES7.39%85 410
VERTEX PHARMACEUTICALS4.41%44 312
REGENERON PHARMACEUTICALS-14.30%33 962
GENMAB12.37%11 081
SAREPTA THERAPEUTICS INC8.36%8 769